<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282073</url>
  </required_header>
  <id_info>
    <org_study_id>MMFPRIMER</org_study_id>
    <nct_id>NCT01282073</nct_id>
  </id_info>
  <brief_title>Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy</brief_title>
  <acronym>MMFPRIMER</acronym>
  <official_title>A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyungpook National University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic
      membranous nephropathy, but has a risk of side effects such as nephrotoxicity. The
      investigators plan to the study to evaluate whether mycophenolate mofetil (MMF) could be a
      reasonable alternative with fewer side effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic membranous nephropathy is most common cause of glomerulonephritis in adults.
      Persistent high grade proteinuria or progressively decrease of renal function is a risk
      factor for end stage renal disease in idiopathic membranous nephropathy. It has been reported
      that cyclosporin in patients with idiopathic membranous nephropathy decreases proteinuria and
      improve renal function. Mycophenolate mofetil is a recently developed immunosuppressive agent
      with fewer side effect than cyclosporin. In this study patients with high risk group of
      progressive idiopathic membranous nephropathy will be treated with mycophenolate mofetil and
      low dose prednisone. The outcome will be compared to controls treated with cyclosporin and
      low dose prednisone.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of complete remission</measure>
    <time_frame>at 48 week after treatment</time_frame>
    <description>Complete remission: Reduction in proteinuria to 200 mg per day with stable serum albumin with more than 3.5 g/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of partial remission</measure>
    <time_frame>at 48 week after treatment</time_frame>
    <description>Partial remission: Reduction in proteinuria to greater than 50 percent of initial values or absolute values of proteinuria between 200 mg and 3.5 g per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>estimated Glomerular filtration rate (eGFR)</measure>
    <time_frame>at 48 week after treatment</time_frame>
    <description>The change of eGFR mesured by Modification of Diet in Renal Disease (MDRD) study equation from baseline to 1 year after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>For 48 weeks after treatment</time_frame>
    <description>A relapse is return of proteinuria to approximately 3.5g/day in patients who had previously undergone a complete or partial remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>at 48 week after treatment</time_frame>
    <description>The change of proteinuria from baseline to 48 week after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>For 48 weeks after treatment</time_frame>
    <description>Any undesired effects of interventional drugs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Glomerulonephritis, Membranous</condition>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil, low dose steroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporin, low dose steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil, low dose steroid</intervention_name>
    <description>Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 ~ 1000 mg bid per day (more than 50kg)
Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day
Duration: 48 weeks</description>
    <arm_group_label>Mycophenolate mofetil, low dose steroid</arm_group_label>
    <other_name>Myconol, MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin, low dose steroid</intervention_name>
    <description>Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100Â±50 ng/ml)
Steroid: same dosage with active comparator goup
Duration: 48 weeks</description>
    <arm_group_label>Cyclosporin, low dose steroid</arm_group_label>
    <other_name>Implanta soft capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with idiopathic membranous nephropathy

          2. The duration of disease is less than twelve months

          3. Patients with persistent proteinuria more than 8 grams per day

          4. Patients who provided informed consent

          5. The cases that satisfy more than three of following items even if proteinuria is less
             than 8 grams per day:

               -  eGFR &lt; 60 ml/min/1.73m2

               -  Hypertension (BP above 140/90mmHg or BP above 120/80 in patients taking
                  anti-hypertensive agents)

               -  24 hours urine protein or spot urine protein/creatinine ratio &gt; 5.0 g/day

               -  Serum albumin (g/dL) &lt; 3.0

               -  Selectivity index &gt; 0.2

        Exclusion Criteria:

          1. Severe digestive organ disease

          2. Allergy history to clinical trial medication and acute or chronic allergy for 4 weeks
             recently.

          3. Clinical history of treatment with other immunosuppressive medication

          4. Probability of pregnancy, breast feeding woman

          5. Uncontrolled hypertension (more than 160/100mmHg)

          6. Uncontrolled systemic disease

          7. Drug addiction or alcoholics within 6 months

          8. eGFR is less than 30ml/min at screening

          9. Abnormal liver function test (more than 3 times above compared with normal value)

         10. Absolute neutrophil count &lt;1,500/mm3 or leukocyte &lt;2,500/mm3 or platelets &lt;100,000/mm3

         11. Secondary membranous nephropathy

         12. Expected life expectancy is less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun-Hee Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hee-Yeon Jung, MD</last_name>
    <phone>+82-10-2536-4106</phone>
    <email>83mayring@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dong-A University Medical Center</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won-Suk An, MD</last_name>
      <email>anws@dau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Won-Suk An, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu-Bok Jin, MD</last_name>
      <email>mdjin922@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yang-Wook Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyu-Bok Jin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee-Yeon Jung, MD</last_name>
      <phone>+82-10-2536-4106</phone>
      <email>83mayring@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Yong-Lim Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sun-Hee Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chan-Duck Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jang-Hee Cho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji-Young Choi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Fatima Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>701-600</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duk-Hyun Lee, MD</last_name>
      <phone>+82-53-940-7221</phone>
      <email>dhlee@fatima.or.kr</email>
    </contact>
    <investigator>
      <last_name>Sung-Ho Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Duk-Hyun Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu Hyang Cho, MD</last_name>
      <email>drtoto@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Kyu Hyang Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yon Su Kim, MD</last_name>
      <email>yonsukim@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Suhnggwoon Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong Ki Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Su Mi Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yon Su Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-Hyun Yoo, MD</last_name>
      <email>YOOSY0316@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Shin-Wook Kang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung Hyeok Han, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tae-Hyun Yoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Pyo Lee, MD</last_name>
      <email>kjwa1@medimail.co.kr</email>
    </contact>
    <investigator>
      <last_name>Chun Soo Lim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun Kyu Oh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jung Pyo Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>682-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Chul Chung, MD</last_name>
      <email>hcjungmd@uuh.ulsan.kr</email>
    </contact>
    <investigator>
      <last_name>Jong-Soo Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun-Chul Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2011</study_first_submitted>
  <study_first_submitted_qc>January 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2011</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University</investigator_affiliation>
    <investigator_full_name>Sun-Hee Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Idiopathic membranous nephropathy</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

